Stockscreener 앱 받기
38.76
3.78%
1.41
시간 외 거래:
39.94
1.18
+3.04%
전일 마감가:
$37.35
열려 있는:
$38.13
하루 거래량:
1.23M
Relative Volume:
1.60
시가총액:
$3.59B
수익:
$4.72M
순이익/손실:
$-277.91M
주가수익비율:
-10.39
EPS:
-3.73
순현금흐름:
$-203.56M
1주 성능:
+8.82%
1개월 성능:
-27.69%
6개월 성능:
-26.40%
1년 성능:
+9.18%
1일 변동 폭
$37.41
$39.08
1주일 범위
$35.76
$39.08
52주 변동 폭
$35.51
$62.53
Crinetics Pharmaceuticals Inc Stock (CRNX) Company Profile
명칭
Crinetics Pharmaceuticals Inc
전화
858-450-6464
주소
10222 BARNES CANYON ROAD, BLDG. #2, SAN DIEGO, CA
CRNX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CRNX
Crinetics Pharmaceuticals Inc
|
38.76 | 3.59B | 4.72M | -277.91M | -203.56M | -3.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Crinetics Pharmaceuticals Inc Stock (CRNX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-03-06 | 개시 | Citigroup | Buy |
| 2024-01-16 | 개시 | Morgan Stanley | Overweight |
| 2023-12-21 | 개시 | Jefferies | Hold |
| 2023-11-20 | 재개 | JP Morgan | Overweight |
| 2023-10-24 | 재개 | Cantor Fitzgerald | Overweight |
| 2023-08-31 | 개시 | Oppenheimer | Outperform |
| 2023-04-24 | 개시 | Piper Sandler | Overweight |
| 2023-03-30 | 개시 | Robert W. Baird | Outperform |
| 2021-11-30 | 개시 | JMP Securities | Mkt Outperform |
| 2021-11-23 | 개시 | Evercore ISI | Outperform |
| 2021-06-18 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2019-12-23 | 개시 | ROTH Capital | Buy |
| 2019-02-14 | 개시 | H.C. Wainwright | Buy |
| 2018-08-13 | 개시 | JP Morgan | Neutral |
| 2018-08-13 | 개시 | Leerink Partners | Outperform |
| 2018-08-13 | 개시 | Piper Jaffray | Overweight |
모두보기
Crinetics Pharmaceuticals Inc 주식(CRNX)의 최신 뉴스
Is Crinetics Pharmaceuticals (CRNX) Among Billionaire Joseph Edelman’s Long-Term Stock Picks? - Insider Monkey
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Sees Large Increase in Short Interest - MarketBeat
Crinetics Pharmaceuticals (NASDAQ:CRNX) Stock Price Down 5.2%Here's Why - MarketBeat
Crinetics Pharmaceuticals, Inc. (CRNX): The Biotech Stock with Biggest Upside Potential - Insider Monkey
12 Biotech Stocks with the Biggest Upside Potential - Insider Monkey
Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) Up 3.12%: This Is What Analysts Are Now Forecasting - Stocks Register
Crinetics falls after mid-stage trial data adrenal disorder therapy - MSN
Crinetics Pharmaceuticals (NASDAQ:CRNX) Receives “Buy” Rating from HC Wainwright - Defense World
Crinetics Pharmaceuticals' (CRNX) Buy Rating Reiterated at HC Wainwright - MarketBeat
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Purchased by JPMorgan Chase & Co. - Defense World
CRNXCrinetics Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
Crinetics Pharmaceuticals Announces January 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Crinetics Pharmaceuticals Grants Stock Options to 17 New Employees in Key Expansion Move - StockTitan
Crinetics reports positive results in CAH treatment study By Investing.com - Investing.com Australia
Crinetics stock falls after CAH therapy data (CRNX:NASDAQ) - Seeking Alpha
Crinetics Pharmaceuticals (NASDAQ:CRNX) Sees Unusually-High Trading VolumeStill a Buy? - MarketBeat
Crinetics Pharmaceuticals Advances Atumelnant After Successful Phase 2 - TipRanks
Crinetics reports positive results in CAH treatment study - Investing.com India
Crinetics Announces Positive Topline Results From Phase 2 - GlobeNewswire
Crinetics' CAH Drug Atumelnant Shows Remarkable 80% Biomarker Reduction in Phase 2 Trial Success - StockTitan
Rare Endocrinology and Metabolic Disorders Market Analysis: Emerging Trends and Future Outlook of Hypophosphatasia, Congenital Adrenal Hyperplasia, and Severe Hypertriglyceridemia | DelveInsight - GlobeNewswire Inc.
Crinetics Pharmaceuticals’ SWOT analysis: stock poised for growth as pipeline advances - Investing.com Nigeria
Crinetics Pharmaceuticals' SWOT analysis: stock poised for growth as pipeline advances - Investing.com India
Crinetics stock maintains rating at Overweight on recent approval By Investing.com - Investing.com Canada
Trading (CRNX) With Integrated Risk Controls - Stock Traders Daily
Crinetics Pharmaceuticals chief sells shares worth $781,350 - Investing.com
Crinetics Pharmaceuticals chief sells shares worth $781,350 By Investing.com - Investing.com Canada
Crinetics Pharmaceuticals (NASDAQ:CRNX) Trading Down 3.5%What's Next? - MarketBeat
Crinetics Pharmaceuticals CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan
Crinetics Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Bought by Principal Financial Group Inc. - Defense World
Principal Financial Group Inc. Raises Position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - MarketBeat
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Crinetics Pharmaceuticals: Attractive Speculative Bet On Market Weakness (NASDAQ:CRNX) - Seeking Alpha
Berkshire Hathaway Cl A (BRK-A-N) QuotePress Release - The Globe and Mail
Stifel Financial Corp Sells 520 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Bought by Geode Capital Management LLC - MarketBeat
Crinetics Pharmaceuticals' SWOT analysis: promising pipeline drives stock outlook - Investing.com
(CRNX) Trading Advice - Stock Traders Daily
Crinetics Pharmaceuticals (NASDAQ:CRNX) Given Market Outperform Rating at JMP Securities - Defense World
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Acquired by Franklin Resources Inc. - MarketBeat
Barclays PLC Acquires 89,358 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - MarketBeat
Neurocrine’s Crenessity Is The First New Drug For CAH In 70 Years - News & Insights
Crinetics Pharmaceuticals names new Chief Commercial Officer By Investing.com - Investing.com Canada
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Short Interest Update - MarketBeat
Crinetics Pharmaceuticals names new Chief Commercial Officer - Investing.com India
Acromegaly Pipeline Trends 2024: Clinical Trials, Therapeutic - openPR
Isabel Kalofonos Joins Crinetics Pharmaceuticals as Chief Commercial Officer - citybiz
Crinetics appoints Isabel Kalofonos as CCO - TipRanks
JMP Securities Reaffirms Market Outperform Rating for Crinetics Pharmaceuticals (NASDAQ:CRNX) - MarketBeat
Crinetics Pharmaceuticals Inc (CRNX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.81%
자본화:
|
볼륨(24시간):